These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10492502)

  • 21. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of cardiac valve dysfunction in obese patients treated with sibutramine.
    Bach DS; Rissanen AM; Mendel CM; Shepherd G; Weinstein SP; Kelly F; Seaton TB; Patel B; Pekkarinen TA; Armstrong WF
    Obes Res; 1999 Jul; 7(4):363-9. PubMed ID: 10440592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sibutramine treatment in obese adolescents: a randomized trial.
    Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
    Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Gómez-Santos R; Campos-Franco E; Berber A
    Adv Ther; 2003; 20(2):101-13. PubMed ID: 12836810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
    JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
    Kim SH; Lee YM; Jee SH; Nam CM
    Obes Res; 2003 Sep; 11(9):1116-23. PubMed ID: 12972682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sibutramine therapy in obese women--effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations.
    Baranowska B; Wolińska-Witort E; Martyńska L; Chmielowska M; Mazurczak-Pluta T; Boguradzka A; Baranowska-Bik A
    Neuro Endocrinol Lett; 2005 Dec; 26(6):675-9. PubMed ID: 16380708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
    Scheen AJ
    Rev Med Liege; 2001 Sep; 56(9):656-9. PubMed ID: 11702509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of weight reduction by sibutramine on female sexual function.
    Kim KK; Kang HC; Kim SS; Youn BB
    Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
    Nisoli E; Carruba MO
    Obes Rev; 2000 Oct; 1(2):127-39. PubMed ID: 12119986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of lifestyle modification and pharmacotherapy for obesity.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Phelan S; Cato RK; Hesson LA; Osei SY; Kaplan R; Stunkard AJ
    N Engl J Med; 2005 Nov; 353(20):2111-20. PubMed ID: 16291981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG; Egri Z
    Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical use of sibutramine.
    Ryan DH
    Drugs Today (Barc); 2004 Jan; 40(1):41-54. PubMed ID: 14988769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of sibutramine in the management of obesity and related disorders: an update.
    Tziomalos K; Krassas GE; Tzotzas T
    Vasc Health Risk Manag; 2009; 5(1):441-52. PubMed ID: 19475780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.